BMS' Opdivo Approval In CRC Overshadowed By Keytruda Dominance
Executive Summary
The US FDA has approved BMS' Opdivo for previously treated patients with some forms of colorectal cancer, however direct competition from Merck's Keytruda may limit its success.
You may also be interested in...
Lack Of Comparative Trials Stymied BMS’s EU Filings For Opdivo In Colorectal, Liver Cancers
Bristol-Myers Squibb’s decision to withdraw its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC) follows a similar move for liver cancer last year. The company now seems to be more interested in pursuing the product’s use in combination with Yervoy and Mekinist in mCRC.
Opdivo’s EU Colorectal Cancer Setback ‘More Than Offset’ By Potential Gains In Combination
Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.
Don't Lose Track: Review And Approval News On Opdivo, Kalydeco And More
US FDA had a busy week. Here's some bullet points of product development events you may have missed.